Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Mitry

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
Cell Reports. Medicine|October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 24, 2022
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancerViolaine Randrian, Simon Pernot, Karine Le Malicot, et al.
Journal of Hepatology|August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinomaTim Meyer, Richard S Finn, Mitesh Borad, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
Cell Reports. Medicine|October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 24, 2022
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancerViolaine Randrian, Simon Pernot, Karine Le Malicot, et al.
Journal of Hepatology|August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinomaTim Meyer, Richard S Finn, Mitesh Borad, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Pageof 12